JP2021533128A5 - - Google Patents

Info

Publication number
JP2021533128A5
JP2021533128A5 JP2021505721A JP2021505721A JP2021533128A5 JP 2021533128 A5 JP2021533128 A5 JP 2021533128A5 JP 2021505721 A JP2021505721 A JP 2021505721A JP 2021505721 A JP2021505721 A JP 2021505721A JP 2021533128 A5 JP2021533128 A5 JP 2021533128A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
spa
composition according
compound
Prior art date
Application number
JP2021505721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533128A (ja
JPWO2020028290A5 (https=
JP7573512B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044023 external-priority patent/WO2020028290A1/en
Publication of JP2021533128A publication Critical patent/JP2021533128A/ja
Publication of JP2021533128A5 publication Critical patent/JP2021533128A5/ja
Publication of JPWO2020028290A5 publication Critical patent/JPWO2020028290A5/ja
Application granted granted Critical
Publication of JP7573512B2 publication Critical patent/JP7573512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021505721A 2018-08-01 2019-07-30 神経変性障害を治療するための方法 Active JP7573512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
US62/713,061 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (4)

Publication Number Publication Date
JP2021533128A JP2021533128A (ja) 2021-12-02
JP2021533128A5 true JP2021533128A5 (https=) 2022-08-04
JPWO2020028290A5 JPWO2020028290A5 (https=) 2022-08-04
JP7573512B2 JP7573512B2 (ja) 2024-10-25

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505721A Active JP7573512B2 (ja) 2018-08-01 2019-07-30 神経変性障害を治療するための方法

Country Status (27)

Country Link
US (2) US12083082B2 (https=)
EP (1) EP3829563B1 (https=)
JP (1) JP7573512B2 (https=)
KR (1) KR102716959B1 (https=)
CN (1) CN112867485A (https=)
AU (1) AU2019315853B2 (https=)
BR (1) BR112021001739A2 (https=)
CL (1) CL2021000269A1 (https=)
DK (1) DK3829563T3 (https=)
EA (1) EA202190406A1 (https=)
ES (1) ES3011716T3 (https=)
FI (1) FI3829563T3 (https=)
HR (1) HRP20250206T1 (https=)
HU (1) HUE070101T2 (https=)
IL (1) IL280424B2 (https=)
LT (1) LT3829563T (https=)
MX (1) MX2021001287A (https=)
MY (1) MY206530A (https=)
PH (1) PH12021550213A1 (https=)
PL (1) PL3829563T3 (https=)
PT (1) PT3829563T (https=)
RS (1) RS66516B1 (https=)
SG (1) SG11202100767XA (https=)
SI (1) SI3829563T1 (https=)
SM (1) SMT202500080T1 (https=)
UA (1) UA130011C2 (https=)
WO (1) WO2020028290A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014121083A1 (en) 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Similar Documents

Publication Publication Date Title
US20250090624A1 (en) Modulators of complement activity
JP2009542611A (ja) アルファ−シヌクレイン凝集の阻害
US20200392181A1 (en) Peptide compositions and related methods
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP2021533128A5 (https=)
JP2004521123A5 (https=)
JP2021527670A5 (https=)
TWI866551B (zh) 穩定抗體組合物
EP3509621A1 (en) Methods of treating iron overload
EP4316595A2 (en) Use of cgrp receptor antagonists in treating glaucoma
JPWO2020028290A5 (https=)
JP7573512B2 (ja) 神経変性障害を治療するための方法
JPWO2019149782A5 (https=)
CN115279341A (zh) 胰高血糖素类似物的液体制剂
TH2101000540A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยกรดซัลโฟโพรพาโนอิกสำหรับการผลิตยาสำหรับการรักษาความผิดปกติที่เกิดจากความเสื่อมของระบบประสาท
JP2023504731A (ja) タウオパチーを処置するためのペプチド組成物及び方法
JP6710416B2 (ja) 炎症性皮膚疾患の予防又は治療剤
JP2001172190A (ja) 乳酸蓄積抑制剤
JP2025538651A (ja) 胃腸管及び/又は内分泌障害治療のためのgalr2作用剤の用途
CN118984715A (zh) 包含新型肽的用于治疗黄斑变性的组合物
CN115974973A (zh) 一种抑制trpm8的多肽及其用途
CN116802208A (zh) 帕金森氏病的治疗
HK40031446B (en) Modulators of complement activity
BR112018012174B1 (pt) Composição farmacêutica que compreende um polipeptídeo inibidor de c5, kit, dispositivo de auto injetor e uso
JP2001172189A (ja) 限界運動量増強剤